NCT/Study#
NCT06594991 /
MSK-24-166
A Phase 2 study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma
DISEASE GROUP:
Skin and Soft Tissue
current phase:
Phase II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
